MedMira Board of Directors Elected at Annual General Meeting

HALIFAX, Feb. 4 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, today announced that the Company's Board of Directors was elected at MedMira's 2011 Annual General and Special Meeting of Shareholders, which was held on January 27th, 2011. Mr. Hermes Chan, Dr. Shou-Ching Tang, Mr. Romano Robusto and Mr. Markus Meile were re-elected as directors of the Company. 

"Under the guidance of our Board of Directors MedMira continues to push forward with its strategic partnership strategy, working with partners on a number of different aspects of the business including marketing and business development, financing, and regional manufacturing hubs," said Hermes Chan, CEO, MedMira. "While MedMira and its partners are experiencing extended sales cycles in some of its developing markets, we do believe that the focus on strategic partnerships is the right path for the Company's long term success.  Initiatives are underway with partners in most major markets around the world."

Dr. James Smith and Mr. Andre Archimbaud did not stand for re-election and consequently ceased to be directors upon completion of the shareholder meeting. 

Mr. Chan continued, "The Board thanks Dr. Smith and Mr. Archimbaud for their service as directors."

Shareholders approved all other matters considered at the meeting including the appointment of PricewaterhouseCoopers LLP as the Company's auditors, ratification of the stock option plan, approval of the year end financial statements, and the issuance of additional shares through private placements over the coming year.

About MedMira

MedMira is a leading developer and manufacturer of flow-through rapid diagnostics and technologies. The Company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for infectious diseases in minutes. MedMira diagnostics are sold under the Reveal®, MiraWell®, Multiplo™, and Miriad brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events.  Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

SOURCE MEDMIRA INC.

For further information:

MedMira Contact: Andrea Young
T.  902-450-1588
E.  ayoung@medmira.com

Profil de l'entreprise

MEDMIRA INC.

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.